#147-Hussein Yassine, M.D.: Deep dive into the “Alzheimer’s gene” (APOE), brain health, and omega-3s

KEYPOINTS

• 01

  The brain is an energy-hungry, lipid-rich organ behind a tight barrier.

  Yassine, a USC physician-scientist studying APOE and brain lipids, notes the brain is about 2% of body weight but uses roughly 20% of the body's energy. Astrocytes take up glucose and fat to fuel neurons, and microglia, immune cells, clear debris such as amyloid. About 40% of the brain's fatty acids are polyunsaturated—DHA, EPA and the omega-6 arachidonic acid.

• 02

  Brain glucose uptake runs through GLUT1, not insulin-driven GLUT4.

  Muscle glucose uptake via GLUT4 responds to insulin, exercise and body weight, but the blood-brain barrier relies mainly on GLUT1, which the brain regulates to protect itself: it lowers GLUT1 in chronic high blood sugar such as type 2 diabetes and raises it in prolonged fasting. Yassine says APOE4 makes GLUT1 less effective at the barrier.

• 03

  APOE regulates the speed of lipid traffic.

  Unlike apoB, a structural protein of lipoproteins, APOE and apoC3 regulate how quickly particles are processed and cleared, including remnants of dietary chylomicrons. APOE4 binds the LRP1 receptor, expressed at the blood-brain barrier, more tightly than E3 or E2. Its multiple roles in the periphery and the brain make it hard to study.

• 04

  APOE4 is the ancestral variant, shaped by diet and infection.

  E4 is the oldest isoform; Attia cites E3 appearing roughly 50,000 years ago and E2 roughly 10,000 years ago. Yassine's view is that E4 was strongly protective against inflammation when humans faced parasites and sepsis, and thrived on a meat- and fish-rich diet in Africa. Migration to Europe and plant-based farming may have pressured it, favoring E3 and E2.

• 05

  The Alzheimer's link was found at Duke around 1988–89.

  Allen Roses's group found Alzheimer's patients had substantially more APOE4, though the variant had been known since the 1960s. Two copies raise Alzheimer's risk about 12-fold; one copy raises it about two- to fourfold. E2 is protective, which makes E2/E4 carriers harder to classify.

• 06

  APOE4 alone may not be sufficient for disease.

  APOE sits on chromosome 19 in a region with about 20–30 co-inherited genes, such as TOMM40 and apoC1, which can modify risk. In one dataset Attia examined, healthy E4 carriers had risk barely above non-carriers, while E4 with diabetes was much higher. Yassine cautions that APOE4 itself promotes insulin resistance with age, so it may help cause the diabetes rather than simply interact with it.

• 07

  Americans eat little DHA, but supplement trials are inconsistent.

  US intake of DHA averages about 100 mg a day, which may not supply enough to the brain. Yet supplement studies conflict, products vary in production, concentration and quality, and most trials last only three months to a year, too short for brain outcomes.

• 08

  REDUCE-IT versus STRENGTH shows how trial design shapes answers.

  REDUCE-IT gave 4 grams of pure EPA to high-risk people with high triglycerides, inspired by Japanese data, and cut cardiovascular events, but its mineral-oil placebo drew criticism that the placebo may have raised risk. STRENGTH used a mostly EPA mix with some DHA versus corn oil and found no difference. Possible explanations include placebo, dose, EPA:DHA ratio, or participants without a deficiency; almost 80% had type 2 diabetes.

• 09

  Young E4 brains crave DHA; older ones lose access.

  When Yassine's team infused labeled DHA into 35-year-old E4 carriers, their brains took up omega-3s avidly. But somewhere between 55 and 70, E4 brains' ability to capture DHA from blood declines—alongside GLUT1 failure and blood-brain-barrier breakdown—suggesting a critical window for prevention.

• 10

  DHA failed in mild Alzheimer's, especially for E4 carriers.

  In a large 2010 JAMA trial led by Joseph Quinn, 2 grams of DHA for 18 months in patients aged 65–80 with mild Alzheimer's had no overall effect. On reanalysis, E4 carriers showed no response while non-carriers appeared to improve on cognitive scores. DHA builds synapses; EPA acts more as an anti-inflammatory signal.

• 11

  Early-life DHA matters most while the brain is growing.

  Yassine notes that large studies in the 1990s linked low DHA in infancy—via formula or diet—to poorer school outcomes, prompting the FDA around 2001–2002 to allow DHA in infant formula. Brain growth slows considerably between ages 6 and 12–13, after which lipid pools are relatively stable. What happens between 6 and 60 is elusive: no large study shows that 35-year-olds eating no omega-3s are in a disease state.